Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.40 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646161 | 1.00 | AKR1C3 (0.40) | AKR1C3AKR1C2GCKMEN1KMT2A | |
| SCHEMBL28819817 | 0.90 | SLC6A4 (0.40) | AKR1C3AKR1C2GCKMEN1KMT2A | |
| SCHEMBL12742235 | 0.88 | GCK (0.38) | AKR1C3AKR1C2GCKMEN1KMT2A | |
| SCHEMBL1867701 | 0.86 | GCK (0.37) | GCKMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1867699 | 0.86 | GCK (0.37) | GCKMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2645258 | 0.85 | ESR1 (0.40) | GCKALDH1A1HPGD | |
| SCHEMBL1858753 | 0.84 | MAOA (0.36) | GCKGRNSORT1APPPSEN1 | |
| SCHEMBL1858751 | 0.84 | MAOA (0.36) | GCKGRNSORT1APPPSEN1 | |
| SCHEMBL1858400 | 0.83 | SLC6A9 (0.42) | AKR1C3AKR1C2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1858397 | 0.83 | SLC6A9 (0.42) | AKR1C3AKR1C2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059522-B1 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6545155-B2 | Useful for increasing insulin secretion in the treatment of type II diabetes | HOFFMANN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-6448399-B1 | 3-CYCLOALKYL- OR PROPYL-2-(3,4-DIHALOPHENYL)-N-QUINOLINYL-, QUINAZOLINYL-, OR QUINOXOLINYL-PROPIONAMIDE. | HOFFMANN-LA ROCHE INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441184-B1 | SUCH AS N-BENZOOXAZOL-2-YL-3-CYCLOPENTYL-2-(4-METHANESULFONYL -PHENYL)-PROPIONAMIDE FOR INCREASING INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | disclosed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | disclosed |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY LEA (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | CORBETT WENDY LEA (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | AKR1C3 2473/4885AKR1C2 1205/4885GCK 2/4885 |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | GCKR, GCK, GPR119 | AKR1C3 2473/4885AKR1C2 1205/4885GCK 2/4885 |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | AKR1C3 1698/4885AKR1C2 2328/4885GCK 3/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | AKR1C3 1240/4885AKR1C2 1512/4885GCK 2/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | AKR1C3 1291/4885AKR1C2 1546/4885GCK 2/4885 |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | AKR1C3 2473/4885AKR1C2 1205/4885GCK 2/4885 |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | AKR1C3 2473/4885AKR1C2 1205/4885GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.